DEFINITIVE CONTRACT
Active75F40126C00123
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$1.9M
obligated · signed 2 weeks ago
EO 14398 - MEDICAL DEVICE COMPANIES FAIL AT RATES UP TO 75% (FALAHAT & FALAHAT, 2024). ACROSS 13 YEARS OF EVALUATING 14,000+ COMPANIES, MTI HAS DOCUMENTED A CONSISTENT CAUSE: FDA MARKET AUTHORIZATION IS NECESSARY BUT RARELY SUFFICIENT. INNOVATORS
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2028
with all options
Loading status
Estimated start: Sep 29, 2027
MEDTECH INNOVATOR
Contract 75F40126C00123
UEI
MMZKW1FL8VM3
Parent Company
MEDTECH INNOVATOR
Capabilities & Certifications
Headquarters Location
Congressional District: 36
Current Obligation
$1,863,392
Base + Exercised Options
$1,863,392
Total Ceiling Value
$1,957,886
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES
PSC
SUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT
Place of Performance
Congressional District: 36
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.